Background Aortic stenosis is a degenerative condition with high mortality in its severe stages and no preventive treatment.

Executives expect a new label indication and a hoped-for easing of hospital capacity constraints to accelerate sales this ...

Edwards Lifesciences shares rise as analyst upgrades stock, citing TAVR growth, margin expansion, and strategic business ...

Coronary events after TAVR are rare but impact survival. PCI improves outcomes, particularly in balloon-expandable valve ...

“The trial demonstrates there may be a greater benefit in treating severe aortic stenosis earlier. In some cases, this would be even before patients begin to experience symptoms. This is the first ...

Abbott recently began conducting the first-in-human procedures for its TAVI system for symptomatic severe aortic stenosis at the Republican Centre of Emergency Medicine in Tashkent, Uzbekistan.

Myval THV matches SAPIEN and Evolut THVs in 30-day outcomes, supporting its role in severe aortic stenosis treatment.

The Navitor Vision, Abbott's latest TAVI system, is designed to improve accuracy during implantation and enhance visibility for interventionists, offering a minimally invasive solution for patients ...

Our Bureau, Mumbai Thursday, January 30, 2025, 15:15 Hrs [IST] ...